rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
10
|
pubmed:dateCreated |
2009-5-4
|
pubmed:abstractText |
Cytotoxic agents streptonigrin and 17-amino-geldanamycin were linked to monoclonal antibodies (mAbs), forming antibody-drug conjugates (ADCs) for antigen-mediated targeting to cancer cells. The drugs were conjugated with a linker construct that is labile to lysosomal proteases and incorporates a valine-alanine-p-aminobenzyl (PAB)-amino linkage for direct attachment to the electron-deficient amine functional groups present in both drugs. The resulting ADCs release drug following internalization into antigen-positive cancer cells. The drug linkers were conjugated to mAbs cAC10 (anti-CD30) and h1F6 (anti-CD70) via alkylation of reduced interchain disulfides to give ADCs loaded with 4 drugs/mAb. The streptonigrin ADCs were potent and immunologically specific on a panel of cancer cell lines in vitro and in a Hodgkin lymphoma xenograft model. We conclude that streptonigrin ADCs are candidates for further research, and that the novel linker system used to make them is well-suited for the conjugation of cytotoxic agents containing electron-deficient amine functional groups.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD30,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD70,
http://linkedlifedata.com/resource/pubmed/chemical/Benzoquinones,
http://linkedlifedata.com/resource/pubmed/chemical/Benzylamines,
http://linkedlifedata.com/resource/pubmed/chemical/Dipeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoconjugates,
http://linkedlifedata.com/resource/pubmed/chemical/Lactams, Macrocyclic,
http://linkedlifedata.com/resource/pubmed/chemical/Streptonigrin,
http://linkedlifedata.com/resource/pubmed/chemical/geldanamycin
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1464-3405
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2650-3
|
pubmed:meshHeading |
pubmed-meshheading:19386499-Animals,
pubmed-meshheading:19386499-Antibodies, Monoclonal,
pubmed-meshheading:19386499-Antigens, CD30,
pubmed-meshheading:19386499-Antigens, CD70,
pubmed-meshheading:19386499-Benzoquinones,
pubmed-meshheading:19386499-Benzylamines,
pubmed-meshheading:19386499-Cell Line, Tumor,
pubmed-meshheading:19386499-Dipeptides,
pubmed-meshheading:19386499-Drug Screening Assays, Antitumor,
pubmed-meshheading:19386499-Humans,
pubmed-meshheading:19386499-Immunoconjugates,
pubmed-meshheading:19386499-Lactams, Macrocyclic,
pubmed-meshheading:19386499-Mice,
pubmed-meshheading:19386499-Streptonigrin,
pubmed-meshheading:19386499-Xenograft Model Antitumor Assays
|
pubmed:year |
2009
|
pubmed:articleTitle |
Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.
|
pubmed:affiliation |
Seattle Genetics, Inc., Bothell, WA 98021, USA. pburke@seagen.com
|
pubmed:publicationType |
Journal Article
|